HistoSonics was chosen as a 2020 Red Herring Top 100 North America Winner. “What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors,” added Alex Vieux, Red Herring's publisher. “Some of the technical wizardry and first-rate business models showcased at the conference has been fantastic to learn about. We believe HistoSonics embodies the drive, skill and passion on which tech thrives. HistoSonics should be proud of its achievement - the competition was incredibly strong.”
The winners have been chosen from thousands of entrants, whittled down to hundreds presenting their companies at the virtual conference on November 17th and 18th. The event, led by Red Herring chairman Alex Vieux, included two days of keynote speeches, discussions and finalist presentations. Industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy, and market penetration judged companies.
Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.
“2020’s crop of Top 100 winners has been among our most intriguing yet,” said Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here, which is in many ways the heartland of the industry, has been a thrilling experience.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.
